Our Clinical Trials

Clinical Trials Database

Clinical trials play an essential role in bringing new treatments to all cancer patients. Our patients who have participated in clinical trials enjoy the reassurance and security they get from close monitoring and are proud to play a part in advancing medicine.

The following clinical trials are being offered through Urologic Consultants of Southeastern Pennsylvania. For more information about these or any other clinical trials, talk with your doctor.

Bladder Cancer
EOquin study
For patients with bladder cancer where the tumor has not invaded the bladder.  The bladder wall is highly susceptible to recurrences. Standard treatment is surgery (transurethral resection of bladder tumor, or TURBT) to remove the tumors. This study will evaluate the effectiveness of a medication, EOquin, to prevent this recurrence. Either EOquin or a placebo will be administered in a single dose through a catheter after surgery. Patients will undergo a cystoscopy every three months for two years to see if the cancer has returned.
Protocol IDs: NCT00461591
Sponsored by Spectrum Pharmaceuticals, Inc.

BPH (benign prostatic hyperplasia)
Proscar/Avodart study
For men age 50 to 80 with BPH who have taken the drug Proscar (finasteride) for at least a year. A randomized group of patients will switch to Avodart (dutasteride) for a year to determine which medication is more effective at shrinking the size of the prostate and improving symptoms. Participants will have their blood drawn at the beginning and end of the study, and will also undergo a transrectal ultrasound of the prostate (TRUSP) at the beginning and end to measure the size of the prostate. All medications will be paid for through the study.
Protocol ID: NCT00690950
Sponsored by Urologic Consultants of Southeastern PA

Prostate Cancer

HIFU Study – Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer.
For men who have been treated for prostate cancer with external beam radiation therapy, now experiencing a rising PSA.  A biopsy and other tests must show that the cancer has returned, but has not spread beyond the prostate. The clinical trial utilizes High Intensity Focused Ultrasound (HIFU), a minimally invasive technique that uses focused ultrasound waves to destroy cancerous tissue. HIFU has been approved for treating prostate cancer in Europe, Canada and other parts of the world. The study requires a minimum of eight office visits and a procedure at Hahnemann University Hospital.  Note that men who received brachytherapy and were treated with seeds may not participate. We are conducting the study in collaboration with Drexel University College of Medicine.
Protocol ID: FSI-003
Sponsored by Sonablate

Taxitere study
For men who have had a radical prostatectomy whose PSA has started to rise again. One group will be treated with Taxotere (docetaxel), Eligard (leuprolide) and Casodex (bicalutamide) for 18 months, while the other group will be treated with Eligard (leuprolide) and Casodex (bicalutamide) for 18 months. Study participants will be followed for five years.
Protocol ID: NCT00514917
Sponsored by Sanofi-Aventis

Degarelix study
For men beginning hormone therapy to reduce the level of testosterone. One group will receive Zoladex (goserelin) three-month dose, while the other group will receive a new three-month dose of Degarelix, which has previously been approved for a one-month dose. Participants will receive four injections over the course of a year. Blood will be drawn monthly to measure testosterone levels.
Protocol ID: NCT00946920
Sponsored by Ferring Pharmaceuticals

Continuum TM device study
For men who will undergo a radical prostatectomy. The device is designed to reattach the bladder and urethra without sutures after removal of the prostate. It holds the tissue together for a week while natural healing takes place, and is then removed. Participants will be checked at four weeks and at six months after the device is removed.
Protocol ID: NCT00894933
Sponsored by American Medical Systems

Overactive Bladder
Astellas study
For men and women who need to go more than eight times in 24 hours, with urgency or incontinence at least part of the time. A new oral medication for reducing urgency and incontinence will be tested over 12 weeks. Participants will need to keep diaries and measure urine output.
Protocol ID: NCT00912964
Sponsored by Astellas Pharma Inc.

Pfizer study
For men and women who need to go frequently overnight, especially with urgency or incontinence. Fesoterodine will be tested for reducing nighttime urgency over 12 weeks. Participants will need to keep diaries.
Protocol ID: NCT00911937
Sponsored by Pfizer

Erectile Dysfunction
Avanafil study with diabetic men
For diabetic men experiencing erectile dysfunction, who do not have prostate cancer, HIV or use recreational drugs. This is a fast-acting oral medication that also leaves the system quickly, allowing for a second dose in 12 hours. Initial test runs 12 weeks. An additional study looking at long-term effectiveness extends the study to one year.
Protocol ID: NCT00809471, NCT00853606
Sponsored by VIVUS, Inc.

Avanafil study with men who have had prostatectomy
For men experiencing erectile dysfunction for at least six months following nerve-sparing prostatectomy. This is a fast-acting oral medication that also leaves the system quickly, allowing for a second dose in 12 hours. Test runs 12 weeks.
Protocol ID: NCT00895011
Sponsored by VIVUS, Inc.